

## Instructions for Authors 2016

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

*Tables.* All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iiaar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iiaar-anticancer.org](mailto:journals@iiaar-anticancer.org)

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online annual subscription to Anticancer Research for the current year. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

### ***Specific information and additional instructions for Authors***

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click [here](#))
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions to authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2015): 64%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).



- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

### General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH. The IIAR is a member of UICC.

### Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

### Selection of Recent Articles

A Mobile Alert System for Preparing the Delivery of Radiation Mitigators. R. DICKSON, J.O. KIM, M.S. HUQ, G. BEDNARZ, J. SUYAMA, D.M. YEALY, H. WANG, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Effects of Targeted Proton Radiation on Spinal Cord in a Porcine Model: A Pilot Study. X.W. MAO, M.J. PECAUT, J.D. CAO, D.S. GRIDLEY (*Loma Linda, CA, USA*)

Novel Prognostic Markers Derived from Cardiovascular Magnetic Resonance Imaging in Patients with Stable Chronic Coronary Artery Disease. C. DOESCH, J. JOCHIMS, F. STREITNER, J. KUSCHYK, I. AKIN, R. LEHMANN, D. LOSSNITZER, M. BEHNES, S.O. SCHOENBERG, M. BORGGREFE, T. PAPAVALASSILIU (*Mannheim, Germany*)

Radical-scavenging and Anti-inflammatory Activity of Quercetin and Related Compounds and Their Combinations Against RAW264.7 Cells Stimulated with *Porphyromonas gingivalis* Fimbriae. Relationships between Anti-inflammatory Activity and Quantum Chemical Parameters. Y. MURAKAMI, A. KAWATA, S. ITO, T. KATAYAMA, S. FUJISAWA (*Sakado, Saitama; Tokyo, Japan*)

Anti-Halitosis Effect of Toothpaste Supplemented with Alkaline Extract of the Leaves of *Sasa senanensis* Rehder. H. SAKAGAMI, K. ONO, Y. KOMINE, T. MIYADAI, Y. TERADA, D. NAKADA, S. TANAKA, M. MATSUMOTO, T. YASUI, K. WATANABE, J. JUNYE, T. NATORI, M. SUGURO-KITAJIMA, H. OIZUMI, T. OIZUMI (*Saitama; Tokyo; Kanagawa, Japan*)

Management of Very Early-onset Fetal Growth Restriction: Results from 92 Consecutive Cases. F. HOELLEN, A. BECKMANN, C. BANZ-JANSEN, J. WEICHERT, A. RODY, M.K. BOHLMANN (*Lübeck; Mannheim, Germany*)

Implementation of a Functional Observation Battery for the Assessment of Postoperative Well being in Rats Subjected to Fimbria-Fornix Transection. L. MARSCHNER, E. WOGENSEN, J. MOGENSEN, K. ABELSON (*Copenhagen, Denmark*)

Decreased Numbers of CD57<sup>+</sup>CD3<sup>-</sup> Cells Identify Potential Innate Immune Differences in Patients with Autism Spectrum Disorder. D. SINISCALCO, T. MIJATOVIĆ, E. BOSMANS, A. CIRILLO, P. KRUZLIAK, V.C. LOMBARDI, K. DE MEIRLEIR, N. ANTONUCCI (*Naples; Caserta; Florence; Bari, Italy; Zellik; Brussels, Belgium; Brno, Czech Republic; Reno, NV, USA*)

Lateral Approach for Excision of Maxillary Incisor Pseudo-Odontoma in Prairie Dogs (*Cynomys ludovicianus*). I. PELIZZONE, G.D. VITOLO, M. D'ACIERNO, D. STEFANELLO, A. FORLANI, G. BROICH (*Reggio Emilia; Milan; Ferrara, Italy*)

PEO-generated Surfaces Support Attachment and Growth of Cells *In Vitro* with No Additional Benefit for Micro-roughness in Sa (0.2-4 µm). O. JUNG, R. SMEETS, A. KOPP, D. PORCHETTA, P. HIESTER, M. HEILAND, R.E. FRIEDRICH, C. PRECHT, H. HANKEN, A. GRÖBE, P. HARTJEN (*Hamburg; Aachen, Germany*)

Quantitative and Functional Requirements for Bioluminescent Cancer Models. L. FEYS, B. DESCAMPS, C. VANHOVE, S. VERMEULEN, J. VANDESOMPELE, K. VANDERHEYDEN, K. MESSENS, M. BRACKE, O. DE WEVER (*Ghent, Belgium*)

Suppressive Activity of Quercetin on Periostin Functions *In Vitro*. S. IRIE, M. KASHIWABARA, A. YAMADA, K. ASANO (*Yokohama, Japan*)

The Prolonged QT Interval: Role of Pro-inflammatory Cytokines, Reactive Oxygen Species and the Ceramide and Sphingosine-1 Phosphate Pathways. P.P. SORDILLO, D.C. SORDILLO, L. HELSON (*Quakertown, PA, USA*)

Specific Antibodies to *Staphylococcus aureus* Biofilm Are Present in Serum from Pigs with Osteomyelitis. L.K. JENSEN, H.E. JENSEN, J. KOCH, T. BJARNSHOLT, S. EICKHARDT, M. SHIRTLIFF (*Copenhagen, Denmark; Baltimore, MD, USA*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

Prevention and Management of Complications During Robotic-assisted Laparoscopic Radical Prostatectomy Following Comprehensive Planning: A Large Series Involving a Single Surgeon. Y.-C. OU, C.-K. YANG, K.-S. CHANG, J. WANG, S.-W. HUNG, M.-C. TUNG, A.K. TEWARI, V.R. PATEL ( <i>Taichung; Taipei, Taiwan, ROC; New York, NY; Orlando, FL, USA</i> ) .....	1991
Totally Laparoscopic Total Gastrectomy <i>Versus</i> Laparoscopically Assisted Total Gastrectomy for Gastric Cancer. E.Y. KIM, H.J. CHOI, J.B. CHO, J. LEE ( <i>Seoul, Republic of Korea</i> ).....	1999
Feasibility of Transanal Minimally Invasive Surgery (TAMIS) for Rectal Tumours and Its Impact on Quality of Life – The Bristol Series. H. SUMRIEN, C. DADNAM, J. HEWITT, K. MCCARTHY ( <i>Bristol; Cardiff, Wales, UK</i> ) .....	2005
Assessment of Surgical Outcome After Pancreatic Resection in Extremely Elderly Patients. Y. SHIRAI, H. SHIBA, T. HORIUCHI, N. SAITO, K. FURUKAWA, T. SAKAMOTO, T. GOCHO, Y. ISHIDA, K. YANAGA ( <i>Tokyo, Japan</i> ).....	2011
Prognosis of Castration-resistant Prostate Cancer Patients – Use of the AdnaTest® System for Detection of Circulating Tumor Cells. O. ČAPOUN, V. MIKULOVÁ, M. JANČÍKOVÁ, H. HONOVÁ, K. KOLOŠTOVÁ, R. SOBOTKA, P. MICHAEL, T. ZIMA, T. HANUŠ, V. SOUKUP ( <i>Prague, Czech Republic</i> ) .....	2019
Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy. P. FRANCO, F. ARCADIPANE, R. RAGONA, M. MISTRANGELO, P. CASSONI, N. RONDI, M. MORINO, P. RACCA, U. RICARDI ( <i>Turin, Italy</i> ).....	2027
Radiotherapy Alone for Malignant Spinal Cord Compression in Young Men with Seminoma. L. BOLM, S. JANSSEN, T. BARTSCHT, D. RADES ( <i>Lübeck, Germany</i> ) .....	2033
Outcomes After Irradiation of Epidural Spinal Cord Compression Due to Metastatic Thyroid Cancer. D. RADES, S. JANSSEN, L. KÄSMANN, L. BOLM, S.E. SCHILD ( <i>Lübeck; Hannover, Germany; Scottsdale, AZ, USA</i> ) .....	2035
Errata .....	2041
Book Reviews .....	2043
Announcements .....	2053



Prognostic Influence of the Extent of Lymph Node Dissection and Perioperative Comorbidities in Patients with Gastric Cancer. T. KAWAGUCHI, S. KOMATSU, D. ICHIKAWA, Y. KIMURA, S. KOMIYAMA, H. KONISHI, S. KIN, S. KAWAKAMI, T. KOSUGA, K. OKAMOTO, E. OTSUJI ( <i>Fukuchiyama; Kyoto, Japan</i> ) .....	1917
Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer. S. KANEKIYO, S. TAKEDA, M. NAKAJIMA, M. NISHIYAMA, M. KITAHARA, Y. SHINDOU, I. MICHIIHISA, T. ABE, S. YOSHINO, S. HAZAMA, H. NAGANO ( <i>Ube, Yamaguchi, Japan</i> ) .....	1923
Chemotherapy-induced Nausea and Vomiting in Patients with Hepatobiliary and Pancreatic Cancer Treated with Chemotherapy: A Prospective Observational Study by the CINV Study Group of Japan. H. NITTA, H. BABA, K. SUGIMORI, J. FURUSE, S. OHKAWA, K. YAMAMOTO, H. MINAMI, M. SHIMOKAWA, G. WAKABAYASHI, K. AIBA ( <i>Kumamoto; Yokohama; Tokyo; Okayama; Hyogo; Fukuoka; Morioka, Japan</i> ) .....	1929
Early Response of Esophageal Cancer to Neoadjuvant Chemotherapy with Docetaxel–Cisplatin–5-Fluorouracil Represents Sensitivity: A Phase II Study. A. MATSUMOTO, K. NISHIKAWA, M. YUDA, Y. TANAKA, Y. TANISHIMA, Y. ARAKAWA, Y. ISHIBASHI, T. SAKUYAMA, N. OMURA, N. MITSUMORI, K. AIBA, K. YANAGA ( <i>Tokyo, Japan</i> ) .....	1937
Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy. P. FRANCO, F. ARCADIPANE, R. RAGONA, M. MISTRANGELO, P. CASSONI, N. RONDI, M. MORINO, P. RACCA, U. RICARDI ( <i>Turin, Italy</i> ) .....	1943
Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer. M. UMEHARA, Y. UMEHARA, K. TAKAHASHI, A. MURATA, S. NISHIKAWA, T. TOKURA, M. MATSUZAKA, R. TANAKA, T. MORITA ( <i>Aomori; Hirosaki, Japan</i> ) ....	1949
Cytogenetic Biomonitoring in Buccal Mucosa Cells from Women Submitted to Chemotherapy After Mastectomy for Breast Cancer. A.C.F. SOUZA, V.H.P. DA SILVA, C. SEIXAS, T.T.D.O. SCUDELLER, M.T.P.D. AMARAL, D.A. RIBEIRO ( <i>Sao Paulo, SP, Brazil</i> ) .....	1955
Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer. S. ARITA, T. SHIRAKAWA, Y. MATSUSHITA, H.K. SHIMOKAWA, G. HIRANO, A. MAKIYAMA, Y. SHIBATA, S. TAMURA, T. ESAKI, K. MITSUGI, H. ARIYAMA, H. KUSABA, K. AKASHI, E. BABA ( <i>Fukuoka; Kitakyushu; Miyazaki; Beppu, Japan</i> ) .....	1959
Searching for New Biomarkers and the Use of Multivariate Analysis in Gastric Cancer Diagnostics. R. KUCERA, D. SMID, O. TOPOLCAN, M. KARLIKOVA, O. FIALA, D. SLOUKA, T. SKALICKY, V. TRESKA, V. KULDA, V. SIMANEK, M. SAFANDA, M. PESTA ( <i>Pilsen, Czech Republic</i> ) .....	1967
Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease – a Pilot Study. J. WINDRICOVA, R. FUCHSOVA, R. KUCERA, O. TOPOLCAN, O. FIALA, J. FINEK, D. SLIPKOVA, M. KARLIKOVA, J. SVOBODOVA ( <i>Pilsen, Czech Republic</i> ) .....	1973
Pancreas Cancer Surgery in Octogenarians – Should We or Should We Not? K. MARSONER, P. KORNPRAT, G. SODECK, J. SCHAGERL, R. LANGEDER, D. CSENGERI, D. WAGNER, H.J. MISCHINGER, J. HAYBAECK ( <i>Graz; Vienna, Austria</i> ) .....	1979
Causes of Cancer Death Among First-Degree Relatives in Japanese Families with Lynch Syndrome. K. TANAKAYA, T. YAMAGUCHI, H. ISHIKAWA, T. HINOI, Y. FURUKAWA, K. HIRATA, Y. SAIDA, M. SHIMOKAWA, M. ARAI, N. MATSUBARA, N. TOMITA, K. TAMURA, K. SUGANO, C. ISHIOKA, T. YOSHIDA, H. ISHIDA, T. WATANABE, K. SUGIHARA ( <i>Iwakuni; Tokyo; Kyoto; Hiroshima; Kitakyushu; Fukuoka; Nishinomiya; Higashiosaka; Utsunomiya; Sendai; Kawagoe, Japan</i> ) .....	1985

Intraoperative Detection of Superficial Liver Tumors by Fluorescence Imaging Using Indocyanine Green and 5-aminolevulinic Acid. M. KAIBORI, K. MATSUI, M. ISHIZAKI, H. IIDA, T. OKUMURA, T. SAKAGUCHI, K. INOUE, T. IKEURA, H. ASANO, M. KON ( <i>Hirakata, Osaka; Kyoto, Japan</i> ) .....	1841
A Study on the Tolerability of Capecitabine plus Oxaliplatin as Adjuvant Chemotherapy. M. NAKANISHI, Y. KURIU, Y. MURAYAMA, T. ARITA, T. KOSUGA, R. MORIMURA, H. KONISHI, S. KOMATSU, A. SHIOZAKI, H. IKOMA, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	1851
Synchronous Large Gastrointestinal Stromal Tumor and Adenocarcinoma in the Stomach Treated with Imatinib Mesylate Followed by Total Gastrectomy. T. NAMIKAWA, E. MUNEKAGE, M. MUNEKAGE, M. MAEDA, T. YATABE, H. KITAGAWA, K. SAKAMOTO, M. OBATAKE, M. KOBAYASHI, K. HANAZAKI ( <i>Kochi, Japan</i> ) .....	1855
Incidental Finding of a Neuroendocrine Tumor Arising from Meckel Diverticulum During Hernia Repair – A Case Report and Literature Review. N. BACALBASA, R. COSTIN, C. ORBAN, L. ILIESCU, I. HURJUI, M. HURJUI, N. NICULESCU, M. CRISTEA, I. BALESU ( <i>Bucharest; Suceava; Craiova, Romania</i> ) .....	1861
Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity. A. PELISSIER, C. BONNEAU, E. CHÉREAU, T.D.L.M. ROUGE, V. FOURCHOTTE, E. DARAI, R. ROUZIER ( <i>Paris; Reims; Marseille; Saint Cloud; Montigny-Le-Bretonneux, France</i> ) .....	1865
Hydration with 15 mEq Magnesium Is Effective at Reducing the Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin ( $\geq 50$ mg/m <sup>2</sup> ) Combination Chemotherapy. Y. YAMAMOTO, K. WATANABE, I. TSUKIYAMA, H. YABUSHITA, K. MATSUURA, A. WAKATSUKI ( <i>Aichi, Japan</i> ) .....	1873
Prognostic Significance of a Minute Amount of Ascites During Chemoradiotherapy for Locally Advanced Pancreatic Cancer. M. SHINOTO, K. NAKAMURA, Y. SHIOYAMA, T. SASAKI, A. NISHIE, Y. ASAYAMA, S. OHGA, T. YOSHITAKE, K. TERASHIMA, K. ASAI, K. MATSUMOTO, H. HONDA ( <i>Tosu; Fukuoka; Hamamatsu, Japan</i> ) .....	1879
Concomitant External-beam Irradiation and Chemotherapy Followed by High-dose Rate Brachytherapy Boost in the Treatment of Squamous Cell Carcinoma of the Vagina: A Single-Center Retrospective Study. C. LALISCIA, M.G. FABRINI, D. DELISHAJ, G. CORAGGIO, R. MORGANTI, R. TANA, F. PAIAR, A. GADDUCCI ( <i>Pisa, Italy</i> ) .....	1885
Magnetic Resonance Imaging for the Pre-Surgical Assessment of Endometrial Cancer: Results in a Routine Clinical Setting, Outside Dedicated Trials; a Cross-sectional Study. J. ARNAIZ, A.-B. MUÑOZ, V. VERNA, I. GONZALEZ-RODILLA, J. SCHNEIDER ( <i>Santander; Valladolid, Spain</i> ) .....	1891
Tumor Index as a Combined Indicator of Tumor Depth and Size in Gastric Cancer. T. OHASHI, S. KOMATSU, D. ICHIKAWA, T. KOSUGA, K. OKAMOTO, H. KONISHI, A. SHIOZAKI, H. FUJIWARA, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	1895
Predictive Value of Growth Factors and Interleukins for Future Liver Remnant Volume and Colorectal Liver Metastasis Volume Growth Following Portal Vein Embolization and Autologous Stem Cell Application. J. FICHTL, V. TRESKA, D. LYSAK, H. MIRKA, P. DURAS, M. KARLIKOVA, T. SKALICKY, J. VODIČKA, O. TOPOLCAN ( <i>Pilsen, Czech Republic</i> ) .....	1901
Neural Analyses Validate and Emphasize the Role of Progesterone Receptor in Breast Cancer Progression and Prognosis. A. CARONONGAN III, B. VENTURINI, D. CANUTI, S. DLAY, R.N.G. NAGUIB, G.V. SHERBET ( <i>Manila, Philippines; Rimini, Italy; Newcastle upon Tyne; Liverpool, UK; Huntington Beach, CA, USA</i> ) .....	1909

Older Age Modifies Oncologic Outcome Following Radiotherapy in Soft-tissue Sarcoma: A Subtype-specific SEER Analysis. N.K. YUEN, C.-S. LI, A.M. MONJAZEB, D. BORYS, R.J. BOLD, R.J. CANTER (Sacramento, CA; Maywood, IL, USA) .....	1745
Retrospective Analysis on the Feasibility and Efficacy of Docetaxel–Cisplatin Therapy for Recurrent Endometrial Cancer. T. NINOMIYA, W. YAMAGAMI, N. SUSUMU, T. MAKABE, K. SAKAI, M. WADA, A. TAKIGAWA, T. CHIYODA, H. NOMURA, F. KATAOKA, A. HIRASAWA, K. BANNO, D. AOKI (Tokyo, Japan) .....	1751
Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer. M. KESHTGARPOUR, W.S. TAN, J. ZWANZIGER, S. AWADALLA, F.G. LANGI, A.Z. DUDEK (Chicago, IL, USA) .....	1759
Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906. T. KIMURA, H. TANIGUCHI, N. WATANABE, H. SAKA, Y. KOGURE, J. SHINDO, T. OGASAWARA, E. KOJIMA, Y. HASEGAWA, M. YAMAMOTO, R. SUZUKI, M. ANDO, M. KONDO, H. SAITO (Seto; Nagoya; Komaki; Toyohashi; Okazaki, Aichi; Ogaki, Gifu, Japan) .....	1767
Impact of Neoadjuvant Chemotherapy Among Patients with Pancreatic Fistula After Gastrectomy for Advanced Gastric Cancer. T. KOSAKA, H. AKIYAMA, H. MAKINO, J. KIMURA, R. TAKAGAWA, H.A. ONO, C. KUNISAKI, I. ENDO (Yokohama, Japan) .....	1773
Laparoscopic Resection of Gastric Cancer in a Patient with Chronic Lymphocytic Leukemia Accompanied by Neutropenia. Y. NAKASHIMA, R. NAKANISHI, M. SUGIYAMA, K. OHGAKI, H. SONODA, H. SAEKI, E. OKI, A. MATSUYAMA, T. MAEDA, S. TSUTSUI, H. MATSUDA, T. ISHIDA, Y. MAEHARA (Fukuoka; Hiroshima, Japan) .....	1779
Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer. T. FUJII, R. YAJIMA, H. TATSUKI, H. KUWANO (Gunma, Japan) ...	1785
Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver. B. NISMAN, L. APPELBAUM, V. YUTKIN, H. NECHUSHTAN, A. HUBERT, B. UZIELY, D. PODE, T. PERETZ (Jerusalem, Israel) .....	1791
Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer. R.S. DAVIES, C. SMITH, J.F. LESTER (Cardiff, Wales, UK) .....	1799
Immunohistochemical Expression of CCR2, CSF1R and MMP9 in Canine Inflammatory Mammary Carcinomas. T.P. RAPOSO, B.C.B. BEIRÃO, I. PIRES, J. PRADA, P. BRILHANTE, D.J. ARGYLE, F.L. QUEIROGA (Vila Real; Porto; Braga, Portugal; Edinburgh, UK) .....	1805
Impact of Chemotherapy on Retroperitoneal Lymph Nodes in Ovarian Cancer. M.-D. KEYVER-PAIK, J.M. ARDEN, C. LÜDERS, T. THIESLER, A. ABRAMIAN, T. HOELLER, T. HECKING, T.H. AYUB, A. DOESER, C. KAISER, W. KUHN (Bonn; Berlin, Germany) .....	1815
Impact of the Radiation Dose and Completion of Palliative Radiotherapy on Survival in Patients Treated for Locally Advanced Lung Cancer. S. JANSSEN, L. KAESMANN, S.E. SCHILD, D. RADES (Lübeck; Hannover, Germany; Scottsdale, AZ, USA) .....	1825
Forecasting Survival Probabilities After Radiotherapy of Metastatic Epidural Spinal Cord Compression from Colorectal Cancer in the Elderly. D. RADES, T. BARTSCHT, S. JANSSEN, A. BAJROVIC, B. SEGEDIN, S.E. SCHILD (Lübeck; Hannover; Hamburg, Germany; Ljubljana, Slovenia; Scottsdale, AZ, USA) .....	1829
Atypical Right Hepatectomy for Liver Metastasis from Ovarian Leiomyosarcoma – A Case Report and Literature Review. N. BACALBASA, C. TARAS, C. ORBAN, L. ILIESCU, I. HURJUI, M. HURJUI, N. NICULESCU, M. CRISTEA, I. BALESU (Bucharest; Suceava; Craiova, Romania) .....	1835



NFκB-Associated Pathways in Progression of Chemoresistance to 5-Fluorouracil in an <i>In Vitro</i> Model of Colonic Carcinoma. M.I. KÖRBER, A. STARIBACHER, I. RATZENBÖCK, G. STEGER, R.M. MADER (Vienna, Austria) .....	1631
Anti-malarial Drugs Primaquine and Chloroquine Have Different Sensitization Effects with Anti-mitotic Drugs in Resistant Cancer Cells. A.-R. CHOI, J.-H. KIM, Y.H. WOO, H.S. KIM, S. YOON (Gyeonggi-do; Suwon, Republic of Korea) .....	1641
Human Serum Albumin Nanoparticles as a Novel Delivery System for Cabazitaxel. G. ZHOU, X. JIN, P. ZHU, J. YAO, Y. ZHANG, L. TENG, R.J. LEE, X. ZHANG, W. HONG (Hangzhou, Zhejiang; Changchun, Jilin, PR China; Columbus, OH, USA) .....	1649
Contribution of DNA Repair Xeroderma Pigmentosum Group D Genotypes to Colorectal Cancer Risk in Taiwan. W.-S. CHANG, T.-C. YUEH, C.-W. TSAI, H.-X. JI, C.-N. WU, S.-C. WANG, Y.-L. LAI, S.-W. HSU, M.-H. HSIEH, C.-L. HSIAO, Y.-W. HUNG, T.-C. SHIH, D.-T. BAU (Taichung; Taipei, Taiwan, ROC) .....	1657
Renieramycin M Sensitizes Anoikis-resistant H460 Lung Cancer Cells to Anoikis. N. SIRIMANGKALAKITTI, S. CHAMNI, K. SUWANBORIRUX, P. CHANVORACHOTE (Bangkok, Thailand) .....	1665
Docosahexaenoic Acid Sensitizes Leukemia Lymphocytes to Barasertib and Everolimus by ROS-dependent Mechanism Without Affecting the Level of ROS and Viability of Normal Lymphocytes. Z. ZHELEV, D. IVANOVA, D. LAZAROVA, I. AOKI, R. BAKALOVA, T. SAGA (Stara Zagora; Sofia, Bulgaria; Chiba, Japan) .....	1673
The Effects of Estradiol and Glucocorticoid on Human Osteosarcoma Cells: Similarities and Differences. Q. ZHOU, L. SHEN, CHAOQUN LIU, CHUNFENG LIU, H. CHEN, J. LIU (Jiangsu; Shanghai, PR China) .....	1683
Nitro-oxidative Stress Is Involved in Anticancer Activity of 17β-Estradiol Derivative in Neuroblastoma Cells. M. GORSKA, A. KUBAN-JANKOWSKA, R. MILCZAREK, M. WOZNIAK (Gdansk, Poland) .....	1693
 <i>Clinical Studies</i>	
The Emerging Non-operative Management of Non-metastatic Rectal Cancer: A Population Analysis. M.J. ABRAMS, P.P. KOFFER, K.L. LEONARD (Boston, MA; Providence, RI, USA) .....	1699
Clinical Outcomes in Patients with Recurrent or Metastatic Human Papilloma Virus-positive Head and Neck Cancer. R.P. DANG, V.H. LE, B.A. MILES, M.S. TENG, E.M. GENDEN, R.L. BAKST, V. GUPTA, D.Y. ZHANG, E.G. DEMICCO, M.R. POSNER, K.J. MISIUKIEWICZ (New York, NY, USA) .....	1703
Risk of Metabolic Complications in Patients with Solid Tumors Treated with mTOR inhibitors: Meta-analysis. S. LEW, R.S. CHAMBERLAIN (Livingston, NJ; Newark, NJ, USA; St. George, Grenada, West Indies) .....	1711
Predictors of Survival in Acute Myeloid Leukemia by Treatment Modality. S. MASTER, R. MANSOUR, S.S. DEVARAKONDA, Z. SHI, G. MILLS, R. SHI (Shreveport, LA; New York, NY, USA) .....	1719
Modified Liver Hanging Maneuver for <i>En-bloc</i> Right-sided Hepatectomy Combined with Total Caudate Lobectomy for Colon-Cancer Liver Metastasis and Hepatocellular Carcinoma. Y. HIROSHIMA, K. MATSUO, D. KAWAGUCHI, Y. KIKUCHI, I. ENDO, K. KODA, S. TOGO, R.M. HOFFMAN, K. TANAKA (Ichihara; Yokohama, Japan; San Diego, CA, USA) .....	1729
Predictive Value of <i>NRAMP1</i> and <i>HGPXI</i> Gene Polymorphism for Maintenance BCG Response in Non-muscle-invasive Bladder Cancer. C. LENORMAND, J. COUTEAU, F.-X. NOUHAUD, G. MAILLET, J. BOU, F. GOBET, C. PFISTER (Rouen; Le Havre, France) .....	1737

Establishment and Characterization of a Pair of Patient-derived Human Non-small Cell Lung Cancer Cell Lines from a Primary Tumor and Corresponding Lymph Node Metastasis. F. GEBAUER, D. WICKLEIN, M. TACHEZY, T. GROB, D. STEINEMANN, G. MANUKJAN, G. GÖHRING, B. SCHLEGELBERGER, H. MAAR, J.R. IZBICKI, M. BOCKHORN, U. SCHUMACHER ( <i>Hamburg; Hannover, Germany</i> ) .....	1507
Psychosocial Outcomes of Quadrantectomy <i>Versus</i> Mastectomy in a Southern Italian Sample: Development and Needs of the Italian Derriford Appearance Scale 24. T. MOSS, A. CHIRICO, L. MALLIA, F. LUCIDI, A. FUCITO, M. D'AIUTO, A. GIORDANO ( <i>Bristol, UK; Philadelphia, PA, USA; Rome; Naples, Italy</i> ) .....	1519
Cytotoxicity Induced by a Redox-silent Analog of Tocotrienol in Human Mesothelioma H2452 Cell Line via Suppression of Cap-dependent Protein Translation. A. SATO, H. UENO, A. TAKASE, A. ANDO, Y. SEKINE, T. YANO ( <i>Chiba; Gunma; Osaka, Japan</i> ) .....	1527
Unfractionated Heparin Selectively Modulates the Expression of CXCL8, CCL2 and CCL5 in Endometrial Carcinoma Cells. A. DOSTER, U. SCHWARZIG, M. ZYGMUNT, J. ROM, F. SCHÜTZ, H. FLUHR ( <i>Heidelberg; Greifswald, Germany</i> ) .....	1535
Vimentin Regulates Invasiveness and Is a Poor Prognostic Marker in Non-small Cell Lung Cancer. A. TADOKORO, N. KANAJI, D. LIU, H. YOKOMISE, R. HABA, T. ISHII, T. TAKAGI, N. WATANABE, N. KITA, N. KADOWAKI, S. BANDO ( <i>Kagawa, Japan</i> ) .....	1545
Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma. S. KAWANO, M. ASANO, Y. ADACHI, J. MATSUI ( <i>Ibaraki, Japan</i> ) .....	1553
Piperazine-based Alpha-1 AR Blocker, Naftopidil, Selectively Suppresses Malignant Human Bladder Cells via Induction of Apoptosis. Y.U. NAKAGAWA, H. NAGAYA, T. MIYATA, Y. WADA, T. OYAMA, A. GOTOH ( <i>Nishinomiya; Sanda, Hyogo, Japan</i> ) .....	1563
Rapid and Specific Screening Assay for <i>KRAS</i> Oncogene Mutation by a Novel Gene Amplification Method. A. KUMASAKA, N. MATSUMOTO, S. MUKAE, T. KITANO, H. NOGUCHI, H. OHKI, K. KOMIYAMA, T. ANDO ( <i>Tokyo, Japan</i> ) .....	1571
HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study. T. MAKATSORIS, A.C. TSAMANDAS, A. STRIMPAKOS, Z. ALEXOPOULOU, D. DIONYSOPOULOS, S. PERVANA, A. KONSTANTARA, P. PAPA KOSTAS, E. SAMANTAS, G. RALLIS, A. DIMOU, G. PENTHEROUDAKIS, K. PAPAPARASKEVA, A. PSYRRI, K.T. KALOGERAS, K. SYRIGOS, C.D. SCOPA, G. FOUNTZILAS ( <i>Patras; Athens; Thessaloniki; Ioannina, Greece; New Haven, CT, USA</i> ) .....	1581
Expression of Podoplanin in Non-melanoma Skin Cancers and Actinic Keratosis. M. WOJCIECHOWSKA-ZDROJOWY, J.C. SZEPIETOWSKI, Ł. MATUSIAK, P. DZIĘGIEL, B. PUŁA ( <i>Wroclaw; Warsaw, Poland</i> ) .....	1591
Implications of Differential Expression of $\beta$ -Catenin in Oral Carcinoma. M.A.G. MOLES, J.A.G. MONTOYA, M.D.M. SALVAGO, I.R. ÁVILA, J.J.P. CAMPILLO, M. BRAVO ( <i>Granada; Jaen, Spain</i> ) .....	1599
Long Non-coding RNA, <i>PANDA</i> , Contributes to the Stabilization of p53 Tumor Suppressor Protein. Y. KOTAKE, K. KITAGAWA, T. OHHATA, S. SAKAI, C. UCHIDA, H. NIIDA, M. NAEMURA, M. KITAGAWA ( <i>Iizuka, Fukuoka; Hamamatsu, Shizuoka, Japan</i> ) .....	1605
Polyphosphoester-based Paclitaxel Complexes: Biological Evaluation. K. HIROTA, T. HRISTOVA, V. MITOVA, T. KODA, M. FUSHIMI, M. KUNIYA, K. MAKINO, H. TERADA, R. CHERKEZOVA, S.-I. YUSA, N. KOSEVA, K. TROEV ( <i>Chiba; Niigata; Hyogo, Japan; Varna; Sofia, Bulgaria</i> ) .....	1613
Discovery of Novel (Imidazo[1,2- <i>a</i> ]pyrazin-6-yl)ureas as Antiproliferative Agents Targeting P53 in Non-small Cell Lung Cancer Cell Lines. M.-A. BAZIN, B. ROUSSEAU, S. MARHADOUR, C. TOMASONI, P. EVENOU, S. PIESARD, A.J. VAISBERG, S. RUCHAUD, S. BACH, C. ROUSSAKIS, P. MARCHAND ( <i>Nantes; Roscoff, France; Lima, Peru</i> ) .....	1621